Apixaban for the Acute Treatment of Venous Thromboembolism in Children

Phase 4 Completed 229 enrolled Bristol-Myers Squibb Pfizer · collab

RandomizedSingle-groupOpen-labelTreatment

To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.

Evaluation	Drug	Modality	Dose	Route
Subject	Apixaban	Small molecule	0.1 mg	Oral
Subject	Apixaban	Small molecule	0.2 mg	Oral
Subject	Apixaban	Small molecule	0.3 mg	Oral
Subject	Apixaban	Small molecule	0.5 mg	Oral
Subject	Apixaban	Small molecule	1 mg	Oral
Subject	Apixaban	Small molecule	1.5 mg	Oral
Subject	Apixaban	Small molecule	2 mg	Oral
Subject	Apixaban	Small molecule	3 mg	Oral
Subject	Apixaban	Small molecule	4 mg	Oral
Subject	Apixaban	Small molecule	5 mg	Oral